Chemical structure of Ceralasertib (AZD6738)

ATR serine/threonine kinase inhibitor

oral agent in Ph. II for cancer

from mTOR-program derived hit + opt.

Clinical Cancer Research

AstraZeneca, Cambridge, UK

The AstraZeneca ATR serine/threonine kinase inhibitor, ceralasertib (AZD6738), is a potent (1 nM biochemical IC50), orally bioavailable, ATP-competitive inhibitor, and is one of the most clinically advanced sulfoximines with ~32 registered clinical…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.